Global Middle East Respiratory Syndrome (MERS) Market, By Product (REGN3048, REGN3051, GLS-5300, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Global Middle East Respiratory Syndrome (MERS) Market Analysis and Size
The Middle East respiratory syndrome (MERS) market is expected to witness significant growth during the forecast period. increased prevalence of MERS, continuous clinical studies going on the to overcome MERS viral infection and strong surveillance & control by the WHO, UNICEF and other government authorities to treat infection will boost up the global middle east respiratory syndrome (MERS) market. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the Middle East respiratory syndrome (MERS) market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Middle East respiratory syndrome (MERS) is a viral respiratory infection caused by the novel coronavirus, also referred as MERS-CoV and first identified in Saudi Arabia in 2012. Coronaviruses are the large family of virus causes common cold, fever to Severe Acute Respiratory Syndrome (SARS). Symptoms of MERS include cough, fever, breathing problem, pneumonia but not always present. Gastrointestinal symptoms, including diarrhea, have also been reported. Some patient of MERS-CoV infection reported asymptomatic (that is they do not have any symptoms of infection) but they are positive for MERS-CoV infection and infect other.
Global Middle East Respiratory Syndrome (MERS) Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product (REGN3048, REGN3051, GLS-5300, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
GeneOne Life Science (South Korea), INOVIO Pharmaceuticals (U.S.), Pfizer Inc.(U.S.), Regeneron Pharmaceuticals Inc (U.S.), Astellas Pharma Inc. (Japan), Merck KGaA (Germany), Sanofi (France), Biocare Medical, LLC (U.S.), Lilly (U.S.), Teva Pharmaceutical Industries Ltd (Israel)
|
|
Market Opportunities
|
|
Global Middle East Respiratory Syndrome (MERS) Market Dynamics
Drivers
- Recent Advances in the Vaccine Development for MERS
The disease is dangerous and becoming more prevalent but still there is no specific treatment proven effective against this viral disease. Several vaccine candidates are developed that gives hope in saving the patients from this dreadful disease. Candidates such as viral vector-based vaccine, subunit vaccine, DNA vaccine, nanoparticle-based vaccine, live-attenuated vaccine and inactivated-whole virus vaccine are expected to improve the immune response of the patients
- Rising Demand for Oral Drugs
Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.
Opportunities
- Increased Clinical Studies and Government Initiatives
Rising awareness about the drugs and studies that are conducted for development in identifying the harmful compositions for the body that by government and private companies for better knowledge of these drugs and antidotes is likely to drive the market growth.
- Increasing Demand for Retail Pharmacies
Rise in the number of narcotic drugs being delivered through retail pharmacies and surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
Restraints/Challenges
- Lack of skilled professionals
The lack of qualified personnel who are unable to treat the patients with these agents could curb the growth of the global Middle East respiratory syndrome (MERS) market over a forecast period.
- High Cost
The huge expenditure associated with these agents surely hamper the market growth.
This global Middle East respiratory syndrome (MERS) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global Middle East respiratory syndrome (MERS) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Middle East Respiratory Syndrome (MERS) Market
Although with the rise in COVID-19, the focus on MERS has been diverted. Hospitals and clinics are getting occupied with COVID-19 patients. The health threats and economic burden caused by these coronaviruses are extremely terrible and getting more serious as the rising number of global infections and attributed deaths of SARS-CoV-2 and MERS-CoV. Thus, COVID-19 left a good impact on the lives of the population.
Global Middle East Respiratory Syndrome (MERS) Market Scope
The Middle East respiratory syndrome (MERS) market is segmented on the product, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- REGN3048
- REGN3051
- GLS-5300
- Others
Route of Administration
- Oral
- Parenteral
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Middle East Respiratory Syndrome (MERS) Market Regional Analysis/Insights
The global Middle East respiratory syndrome (MERS) market is analysed and market size insights and trends are provided by product, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global Middle East respiratory syndrome (MERS) market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing a positive growth for global Middle East respiratory syndrome (MERS) market throughout the forecasted period due to the global leaders in research and development activities, established framework of approval process and increase in number of FDA approval drugs.
North America dominates the market due to presence of advanced technology, affordable reimbursement scenario encourages growth and high R&D & healthcare expenditure.
Middle-East and Asia-Pacific has the largest lucrative growth due to presence of generic manufacturers and increased prevalence of respiratory infections.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Middle East Respiratory Syndrome (MERS) Market Share Analysis
The global Middle East respiratory syndrome (MERS) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global Middle East respiratory syndrome (MERS) market
Key players operating in the global Middle East respiratory syndrome (MERS) market include:
- GeneOne Life Science (South Korea)
- INOVIO Pharmaceuticals (U.S.)
- Pfizer Inc.(U.S.)
- Regeneron Pharmaceuticals Inc (U.S.)
- Astellas Pharma Inc. (Japan)
- Merck KGaA (Germany)
- Sanofi (France)
- Biocare Medical, LLC (U.S.)
- Lilly (U.S.)
- Teva Pharmaceutical Industries Ltd (Israel)
SKU-